Trial Profile
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 28 Dec 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Dec 2021.
- 14 Apr 2021 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.